CASE STUDY: Optimizing T Cell Engaging Therapies from Preclinical Study to Human Clinical Trial: Conditional Activation of T Cell in the Tumor Microenvironment by a Novel 4-1BB T Cell Engaging BsAb (Grabody T)

·       The Grabody T platform: A Clinically Validated 4-1BB Bispecific Antibody Approach to Overcome Liver Toxicity

·       Grabody T Exhibits TAA-Dependent 4-1BB Activation and Strong in vivo Efficacy

·       Promising Clinical Activity and Favourable Safety Profile Across the Grabody T Pipeline (Givastomig, Ragistomig, and YH32367)